We then analyzed the synergistic effect of the VEGF polymorphisms and clinical factors (i.e., HTN, DM, hemoglobin A1c, smoking, BMI, hyperlipidemia, MetS, folate, and homocysteine) on CAD risk (Table S7). The gene discussed is VEGFA; the disease is hyperlipidemia.